novartis_outside_1

Novartis cuts more than 2500 jobs in Switzerland and the UK

pharmafile | September 25, 2018 | News story | Manufacturing and Production Basel, Jobs, Novartis, Switzerland, grimsby, manufacturing 

Swiss multinational Novartis are set to cut thousands of jobs across Europe in an effort to boost profitability. The move comes as part of a major restructuring which will take place over the next four years.

The multibillion pound drugmaker announced today that they are culling 2,200 employees from their 13,000 person strong Swiss workforce, while news got out that a further 400 workers are set to lose their jobs in Grimsby in the North of England.

In total 1,500 jobs will be cut from production sites in Switzerland, in Basel, Stein, Locarno and Schweizerhalle, while a further 700 business services positions are set to be transferred elsewhere. Meanwhile 400 workers are set to lose their jobs in the United Kingdom, as Novartis’ Grimsby production plant is scheduled for closure by 2020.

Advertisement

The Grimsby plant, which has been in production for more than half a century, is one of the town’s most stable employers.  

In a statement the company said “Novartis has been a part of the Grimsby community for many years so this has been a very difficult decision. The Grimsby site is an effective, well-running operation that is testament to the hard-working and dedicated employees.”

Novartis also made clear that the closure was not related to Brexit but was instead part of major restructuring as part of an effort to increase profitability around the world.

Louis Goss

Related Content

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

drug-trials

Novartis candidate for Sjögren’s disease presents positive results

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

Mosquito image

First malaria medicine for infants under 4.5kg receives approval

Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …

The Gateway to Local Adoption Series

Latest content